ACET Aceto Corporation

ACETO Corporation Schedules Fourth Quarter & Fiscal 2018 Financial Results News Release and Conference Call

ACETO Corporation Schedules Fourth Quarter & Fiscal 2018 Financial Results News Release and Conference Call

PORT WASHINGTON, N.Y., Aug. 30, 2018 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the fourth quarter and full year of fiscal 2018 ended June 30, 2018 after the stock market close on Wednesday, September 12, 2018.

Management will host a conference call to discuss the operating and financial results at 9:00 a.m. ET on Thursday, September 13, 2018. To participate in the conference call, please dial 844-413-3976 or 412-317-6583 approximately 10 minutes prior to the call and ask for the ACETO Corporation call. 

To preregister, go to . Callers who preregister will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may preregister at any time, including up to and after the call start time.

A live webcast of the conference call will be available in the Investor Relations section of the Company’s website, . Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

A telephone replay of the conference call will be available from 11:00 a.m. ET on September 13, 2018 until 11:59 p.m. ET on September 21, 2018 and may be accessed by calling 877-344-7529 or 412-317-0088 and reference conference ID #10121909. An archived replay of the conference call will also be available in the investor relations section of the Company’s website.

ABOUT ACETO

ACETO Corporation, incorporated in 1947, is focused on the global marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceutical products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products). With business operations in nine countries, ACETO distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. ACETO's global operations, including a staff of 25 in China and 12 in India, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities.

FORWARD LOOKING STATEMENTS

This news release contains forward-looking statements as that term is defined in the federal securities laws. The events described in ACETO’s forward-looking statements may not occur. Generally, ACETO’s forward-looking statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of ACETO’s plans or strategies, financing plans, projected or anticipated benefits from acquisitions that ACETO may make, or a projection involving anticipated revenues, earnings or other aspects of ACETO’s operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. ACETO intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO’s reports filed with the Securities and Exchange Commission (“SEC”), including, but not limited to, ACETO’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 and other SEC filings. Copies of these filings are available at

ACETO’s actual results, performance and achievements could differ materially from those expressed or implied in ACETO’s forward-looking statements. ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

Investor Relations Contact:

LHA

Jody Burfening



(212) 838-3777

EN
30/08/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aceto Corporation

MarketLine Department
  • MarketLine Department

Prinova Group LLC - Company Profile and SWOT Analysis

Summary Prinova Group LLC - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Prinova Group LLC (Prinova) manufactures and distributes ingredient and flavor solutions. The company's product portfolio includes acidulants, antioxidants, amino acids, botanical extracts, colors, es...

MarketLine Department
  • MarketLine Department

Disproquima SA - Strategy, SWOT and Corporate Finance Report

Summary Disproquima SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Disproquima SA (Disproquima) is a marketer and distributor of wide range of functional ingredients. The company’s product portfolio includes active pharmaceutical ingredients, vitamins and mine...

Adicet Bio Inc: 2 directors

A director at Adicet Bio Inc bought 5,000 shares at 2.400USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

ACETO Completes the Sale of Its Chemicals Business Assets

ACETO Completes the Sale of Its Chemicals Business Assets PORT WASHINGTON, N.Y., April 30, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ) announced today that it has completed the previously disclosed sale of its chemicals business assets to an affiliate of New Mountain Capital, a leading growth-oriented investment firm with over $20 billion in assets under management. The purchase price paid in the transaction consisted of cash plus the payment of cure costs and the assumption of certain liabilities.  ACETO used a portion of the proceeds from the transaction to repay 100% of ...

 PRESS RELEASE

ACETO to Sell its Chemicals Business Assets to New Mountain Capital

ACETO to Sell its Chemicals Business Assets to New Mountain Capital PORT WASHINGTON, N.Y., April 15, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has agreed to sell its chemicals business assets to an affiliate of New Mountain Capital (“NMC”), a leading growth-oriented investment firm with over $20 billion in assets under management. The asset purchase agreement was entered into following ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch